- Conditions
- Multiple Myeloma and Plasma Cell Neoplasm
- Interventions
- fluphenazine hydrochloride
- Drug
- Lead sponsor
- Immune Control
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2006
- U.S. locations
- 3
- States / cities
- Hackensack, New Jersey • New Hyde Park, New York • Philadelphia, Pennsylvania
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1321–1344
of 3,305
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Diabetic Foot Ulcers, Pressure Ulcers
- Interventions
- HP828-101, Hydrogel/Hydrocolloid
- Device
- Lead sponsor
- Healthpoint
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 88 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2011
- U.S. locations
- 11
- States / cities
- Bakersfield, California • Chula Vista, California • Fresno, California + 7 more
- Conditions
- Fabry Disease
- Interventions
- GZ/SAR402671
- Drug
- Lead sponsor
- Genzyme, a Sanofi Company
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 3
- States / cities
- Atlanta, Georgia • Cincinnati, Ohio • Fairfax, Virginia
- Conditions
- Peripheral Vascular Disease
- Interventions
- Absolute Pro™ Peripheral Self-Expanding Stent System
- Device
- Lead sponsor
- Abbott Medical Devices
- Industry
- Eligibility
- 18 Years to 89 Years
- Enrollment
- 151 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2014
- U.S. locations
- 1
- States / cities
- Santa Clara, California
- Conditions
- Stroke, Chronic Stroke, Walking, Difficulty, Gait, Hemiplegic
- Interventions
- Backward Locomotion Treadmill Training (BLTT)
- Behavioral
- Lead sponsor
- University of Cincinnati
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 44 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 1
- States / cities
- Cincinnati, Ohio
- Conditions
- Atrial Fibrillation
- Interventions
- propafenone, flecainide, dofetilide, sotolol, Pulmonary vein ablation, Amiodarone
- Drug · Device
- Lead sponsor
- ProRhythm, Inc.
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 240 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2011
- U.S. locations
- 20
- States / cities
- Fullerton, California • Los Angeles, California • Atlanta, Georgia + 16 more
- Conditions
- Cardiovascular Disease, Diabetes, Breast Cancer, Depression, Mental Health Disorder, Prostatic Hypertrophy, Benign, Parkinson's Disease, Epilepsy
- Interventions
- RxTimerCap, Take-N-Slide, Pillbox
- Behavioral
- Lead sponsor
- Brigham and Women's Hospital
- Other
- Eligibility
- 18 Years to 64 Years
- Enrollment
- 53,480 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 1
- States / cities
- Woonsocket, Rhode Island
- Conditions
- Tricuspid Regurgitation, Tricuspid Valve Disease, Tricuspid Valvular Disorders
- Interventions
- VDyne Transcatheter Tricuspid Valve Replacement System
- Device
- Lead sponsor
- VDyne, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2031
- U.S. locations
- 10
- States / cities
- Los Angeles, California • Detriot, Michigan • Minneapolis, Minnesota + 7 more
- Conditions
- Diabetic Foot Ulcer, Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus (T2DM), Neuroischemic Foot Ulcer, Chronic Wound of the Lower Limb (Leg Ulcer or Foot Ulcer), Chronic Wound Care
- Interventions
- Platelet Rich Plasma
- Device
- Lead sponsor
- Estar Medical dba Medical Technologies, LTD
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 2
- States / cities
- Corpus Christi, Texas
- Conditions
- Stroke, Hemiparesis
- Interventions
- Action Observation + Repetitive Task Practice, Placebo Video + Repetitive Task Practice
- Behavioral
- Lead sponsor
- Ohio State University
- Other
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(15;17)(q22;q12), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma, Childhood Acute Lymphoblastic Leukemia in Remission, Childhood Acute Myeloid Leukemia in Remission, Childhood Burkitt Lymphoma, Childhood Chronic Myelogenous Leukemia, Childhood Diffuse Large Cell Lymphoma, Childhood Immunoblastic Large Cell Lymphoma, Childhood Myelodysplastic Syndromes, Childhood Nasal Type Extranodal NK/T-cell Lymphoma, Chronic Phase Chronic Myelogenous Leukemia, Contiguous Stage II Adult Burkitt Lymphoma, Contiguous Stage II Adult Diffuse Large Cell Lymphoma, Contiguous Stage II Adult Diffuse Mixed Cell Lymphoma, Contiguous Stage II Adult Immunoblastic Large Cell Lymphoma, Contiguous Stage II Adult Lymphoblastic Lymphoma, Contiguous Stage II Grade 3 Follicular Lymphoma, Contiguous Stage II Mantle Cell Lymphoma, de Novo Myelodysplastic Syndromes, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Nodal Marginal Zone B-cell Lymphoma, Noncontiguous Stage II Adult Burkitt Lymphoma, Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma, Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma, Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma, Noncontiguous Stage II Adult Lymphoblastic Lymphoma, Noncontiguous Stage II Grade 3 Follicular Lymphoma, Noncontiguous Stage II Mantle Cell Lymphoma, Previously Treated Myelodysplastic Syndromes, Prolymphocytic Leukemia, Recurrent Adult Burkitt Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult Diffuse Mixed Cell Lymphoma, Recurrent Adult Grade III Lymphomatoid Granulomatosis, Recurrent Adult Immunoblastic Large Cell Lymphoma, Recurrent Adult Lymphoblastic Lymphoma, Recurrent Childhood Anaplastic Large Cell Lymphoma, Recurrent Childhood Grade III Lymphomatoid Granulomatosis, Recurrent Childhood Large Cell Lymphoma, Recurrent Childhood Lymphoblastic Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Small Lymphocytic Lymphoma, Refractory Anemia, Refractory Anemia With Excess Blasts, Refractory Anemia With Excess Blasts in Transformation, Refractory Chronic Lymphocytic Leukemia, Refractory Multiple Myeloma, Secondary Acute Myeloid Leukemia, Secondary Myelodysplastic Syndromes, Splenic Marginal Zone Lymphoma, Stage I Adult Burkitt Lymphoma, Stage I Adult Diffuse Large Cell Lymphoma, Stage I Adult Diffuse Mixed Cell Lymphoma, Stage I Adult Immunoblastic Large Cell Lymphoma, Stage I Adult Lymphoblastic Lymphoma, Stage I Childhood Lymphoblastic Lymphoma, Stage I Grade 3 Follicular Lymphoma, Stage I Mantle Cell Lymphoma, Stage II Childhood Lymphoblastic Lymphoma, Stage III Adult Burkitt Lymphoma, Stage III Adult Diffuse Large Cell Lymphoma, Stage III Adult Diffuse Mixed Cell Lymphoma, Stage III Adult Immunoblastic Large Cell Lymphoma, Stage III Adult Lymphoblastic Lymphoma, Stage III Childhood Lymphoblastic Lymphoma, Stage III Grade 3 Follicular Lymphoma, Stage III Mantle Cell Lymphoma, Stage IV Adult Burkitt Lymphoma, Stage IV Adult Diffuse Large Cell Lymphoma, Stage IV Adult Diffuse Mixed Cell Lymphoma, Stage IV Adult Immunoblastic Large Cell Lymphoma, Stage IV Adult Lymphoblastic Lymphoma, Stage IV Childhood Lymphoblastic Lymphoma, Stage IV Grade 3 Follicular Lymphoma, Stage IV Mantle Cell Lymphoma
- Interventions
- cyclophosphamide, fludarabine phosphate, cyclosporine, mycophenolate mofetil, ex-vivo umbilical cord blood expansion, double-unit umbilical cord blood transplantation, biopsy, immunologic technique, diagnostic laboratory biomarker analysis
- Drug · Other · Procedure
- Lead sponsor
- Fred Hutchinson Cancer Center
- Other
- Eligibility
- 6 Months to 45 Years
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2006
- U.S. locations
- 4
- States / cities
- Duarte, California • Aurora, Colorado • Denver, Colorado + 1 more
- Conditions
- Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Aggressive Non-Hodgkin Lymphoma, Chronic Myelogenous Leukemia, Chronic Phase Chronic Myelogenous Leukemia, Indolent Non-Hodgkin Lymphoma, Lymphoma, Mixed Phenotype Acute Leukemia, Myelodysplastic Syndrome, Myeloproliferative Neoplasm, Recurrent Chronic Lymphocytic Leukemia, Recurrent Follicular Lymphoma, Recurrent Lymphoplasmacytic Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Plasma Cell Myeloma, Recurrent Small Lymphocytic Lymphoma, Recurrent T-Cell Non-Hodgkin Lymphoma, Refractory Chronic Lymphocytic Leukemia, Refractory Chronic Myelogenous Leukemia, Refractory Follicular Lymphoma, Refractory Hodgkin Lymphoma, Refractory Lymphoplasmacytic Lymphoma, Refractory Mantle Cell Lymphoma, Refractory Small Lymphocytic Lymphoma, T-Cell Non-Hodgkin Lymphoma
- Interventions
- Allogeneic Hematopoietic Stem Cell Transplantation, Cyclophosphamide, Cyclosporine, Fludarabine Phosphate, Laboratory Biomarker Analysis, Mycophenolate Mofetil, Total-Body Irradiation, Umbilical Cord Blood Transplantation
- Procedure · Drug · Other + 1 more
- Lead sponsor
- Fred Hutchinson Cancer Center
- Other
- Eligibility
- Up to 69 Years
- Enrollment
- 73 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2018
- U.S. locations
- 6
- States / cities
- Aurora, Colorado • Denver, Colorado • Salt Lake City, Utah + 2 more
- Conditions
- Sleep Apnea, Atrial Fibrillation
- Interventions
- Continuous Positive Airway Pressure
- Other
- Lead sponsor
- The Cleveland Clinic
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 317 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012 – 2017
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- RENAL INSUFFICIENCY, CHRONIC, LIVER FAILURE, ACUTE, HEART DISEASE
- Interventions
- ProQuad
- Biological
- Lead sponsor
- Medical University of South Carolina
- Other
- Eligibility
- 6 Months to 24 Months
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 1
- States / cities
- Charleston, South Carolina
- Conditions
- Hereditary Angioedema
- Interventions
- CINRYZE with rHuPH20
- Biological
- Lead sponsor
- Shire
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011
- U.S. locations
- 4
- States / cities
- Scottsdale, Arizona • Walnut Creek, California • Atlanta, Georgia + 1 more
- Conditions
- Peripheral Arterial Disease, Diabetic Foot Ulcer
- Interventions
- PDA-002
- Biological
- Lead sponsor
- Celularity Incorporated
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2017
- U.S. locations
- 12
- States / cities
- Phoenix, Arizona • Los Angeles, California • Palo Alto, California + 9 more
- Conditions
- Diabetic Macular Edema
- Interventions
- NOVA63035 "Corticosteroid"
- Drug
- Lead sponsor
- Santen SAS
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2011
- U.S. locations
- 1
- States / cities
- Indianapolis, Indiana
- Conditions
- Coronary Artery Disease, Carotid Artery Disease, Peripheral Artery Disease
- Interventions
- Niacin, Placebo
- Drug
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 45 Years and older
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Atherosclerosis
- Interventions
- SB 480848, tablets
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 67 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2007
- U.S. locations
- 4
- States / cities
- Cypress, California • Normal, Illinois • North Dartmouth, Massachusetts + 1 more
- Conditions
- Cancer
- Interventions
- palivizumab, ribavirin
- Biological · Drug
- Lead sponsor
- Fred Hutchinson Cancer Center
- Other
- Eligibility
- Not listed
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1999 – 2001
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Multiple Myeloma
- Interventions
- Investigational drug
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- U.S. locations
- 5
- States / cities
- Los Angeles, California • Rancho Mirage, California • Cleveland, Ohio + 1 more
- Conditions
- Cerebral Palsy, Intraventricular Hemorrhage, Periventricular Leukomalacia, Pulmonary Edema, Abruptio Placentae
- Interventions
- magnesium sulfate
- Drug
- Lead sponsor
- The George Washington University Biostatistics Center
- Other
- Eligibility
- Female only
- Enrollment
- 2,136 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1997 – 2007
- U.S. locations
- 17
- States / cities
- Birmingham, Alabama • Miami, Florida • Chicago, Illinois + 14 more
- Conditions
- Subarachnoid Hemorrhage, Acute Kidney Injury
- Interventions
- Sodium chloride /sodium acetate (16.4%), Sodium chloride (23.4%), PlasmaLyte
- Drug
- Lead sponsor
- Emory University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 59 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
- Conditions
- Neoplasms
- Interventions
- Letetresgene autoleucel, Letetresgene autoleucel with pembrolizumab, Fludarabine, Cyclophosphamide, Pembrolizumab
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 5
- States / cities
- Duarte, California • Miami, Florida • Tampa, Florida + 2 more